Overexpression of Hypoxia-inducible Factor 1alpha in Common Human Cancers and Their Metastases
Overview
Authors
Affiliations
Neovascularization and increased glycolysis, two universal characteristics of solid tumors, represent adaptations to a hypoxic microenvironment that are correlated with tumor invasion, metastasis, and lethality. Hypoxia-inducible factor 1 (HIF-1) activates transcription of genes encoding glucose transporters, glycolytic enzymes, and vascular endothelial growth factor. HIF-1 transcriptional activity is determined by regulated expression of the HIF-1alpha subunit. In this study, HIF-1alpha expression was analyzed by immunohistochemistry in 179 tumor specimens. HIF-1alpha was overexpressed in 13 of 19 tumor types compared with the respective normal tissues, including colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate, and renal carcinomas. HIF-1alpha expression was correlated with aberrant p53 accumulation and cell proliferation. Preneoplastic lesions in breast, colon, and prostate overexpressed HIF-1alpha, whereas benign tumors in breast and uterus did not. HIF-1alpha overexpression was detected in only 29% of primary breast cancers but in 69% of breast cancer metastases. In brain tumors, HIF-1alpha immunohistochemistry demarcated areas of angiogenesis. These results provide the first clinical data indicating that HIF-1alpha may play an important role in human cancer progression.
Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies.
Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M Onco Targets Ther. 2025; 18:233-262.
PMID: 39989503 PMC: 11846535. DOI: 10.2147/OTT.S493643.
Malcolm J, Bridge K, Holding A, Brackenbury W BMC Genomics. 2025; 26(1):59.
PMID: 39838295 PMC: 11748566. DOI: 10.1186/s12864-025-11216-6.
HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects.
Shi Y, Gilkes D Cell Mol Life Sci. 2025; 82(1):44.
PMID: 39825916 PMC: 11741981. DOI: 10.1007/s00018-024-05537-0.
Targeting KRAS: from metabolic regulation to cancer treatment.
Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M Mol Cancer. 2025; 24(1):9.
PMID: 39799325 PMC: 11724471. DOI: 10.1186/s12943-024-02216-3.
Jia Y, Sun Q, Wang Y, Jiang H, Xiao X Medicine (Baltimore). 2024; 103(48):e40508.
PMID: 39612428 PMC: 11608659. DOI: 10.1097/MD.0000000000040508.